Mesoblast Share Price (NASDAQ: MESO)

$13.81

▲

-2.14

(-13.42%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Mesoblast Stock chart to analyse performance

Mesoblast stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$13.55
Today's High:$14.08
$13.81
1.88%
Downside
Day's Volatility :3.76%
Upside
1.92%
52 Weeks Low:$6.00
52 Weeks High:$22.00
$13.81
56.55%
Downside
52 Weeks Volatility :72.73%
Upside
37.23%

Mesoblast Stock Returns

Period	Mesoblast	Sector (Health Care)	Index (Russel 2000)
3 Months	33.43%	3.6%	0.0%
6 Months	-10.12%	-7.7%	0.0%
1 Year	99.28%	-12.6%	0.0%
3 Years	129.3%	9.5%	-4.7%

Mesoblast Key Stats

Check Mesoblast key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$15.95
Open	$14.01
Today's High	$14.08
Today's Low	$13.55
Market Capitalization	$2.1B
Today's Volume	$457.8K
52 Week High	$22.0
52 Week Low	$6.0
Revenue TTM	$5.7M
EBITDA	$-49.4M
Earnings Per Share (EPS)	$-1.31
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-21.31%

Stock Returns calculator for Mesoblast Stock including INR - Dollar returns

The Mesoblast stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Mesoblast investment value today

Current value as on today

₹2,10,180

Returns

₹1,10,180

(+110.18%)

Returns from Mesoblast Stock

₹1,04,896 (+104.9%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Mesoblast Stock

-82%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Mesoblast Stock from India on INDmoney has decreased by -82% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Mesoblast

Name
Holdings %
Name
Holdings %
BlackRock Inc
0.56%
Morgan Stanley - Brokerage Accounts
0.43%
Citadel Advisors Llc
0.38%
Goldman Sachs Group Inc
0.32%
Susquehanna International Group, LLP
0.20%
Summit X, LLC
0.15%

Analyst Recommendation on Mesoblast Stock

Rating

Trend

Buy

77%Buy

22%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Mesoblast(by analysts ranked 0 to 5 stars)

Mesoblast Share Price Target

What analysts predicted

Upside of 95.51%

Target:

$27.00

Current:

$13.81

Mesoblast share price target is $27.00, a slight Upside of 95.51% compared to current price of $13.81 as per analysts' prediction.

Mesoblast Stock Insights

Price Movement
In the last 7 days, MESO stock has moved down by -12.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 1.25M → 1.57M (in $), with an average increase of 10.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -27.70M → -23.96M (in $), with an average increase of 7.8% per quarter

Mesoblast Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$16.7M	↓ 3.57%
Net Income	$-89.8M	↑ 154.46%
Net Profit Margin	-537.01%	↓ 333.5%

	FY20	Y/Y Change
Revenue	$32.2M	↑ 92.3%
Net Income	$-77.9M	↓ 13.21%
Net Profit Margin	-242.38%	↑ 294.63%

	FY21	Y/Y Change
Revenue	$7.5M	↓ 76.81%
Net Income	$-98.8M	↑ 26.78%
Net Profit Margin	-1.3K%	↓ 1082.87%

	FY22	Y/Y Change
Revenue	$10.2M	↑ 36.95%
Net Income	$-91.3M	↓ 7.55%
Net Profit Margin	-894.59%	↑ 430.66%

	FY23	Y/Y Change
Revenue	$7.5M	↓ 26.54%
Net Income	$-81.9M	↓ 10.35%
Net Profit Margin	-1.1K%	↓ 197.12%

	FY24	Y/Y Change
Revenue	$5.9M	↓ 21.32%
Net Income	$-88.0M	↑ 7.41%
Net Profit Margin	-1.5K%	↓ 398.56%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Revenue	$1.7M	↓ 20.8%
Net Income	$-16.3M	↓ 25.77%
Net Profit Margin	-960.42%	↑ 64.31%

	Q4 FY23	Q/Q Change
Revenue	$1.7M	↑ 0.0%
Net Income	$-16.3M	↑ 0.0%
Net Profit Margin	-960.42%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$1.3M	↓ 25.8%
Net Income	$-27.7M	↑ 70.31%
Net Profit Margin	-2.2K%	↓ 1243.92%

	Q2 FY24	Q/Q Change
Revenue	$1.3M	↑ 0.0%
Net Income	$-27.7M	↑ 0.0%
Net Profit Margin	-2.2K%	↑ 0.0%

	Q3 FY24	Q/Q Change
Revenue	$1.6M	↑ 25.54%
Net Income	$-24.0M	↓ 13.5%
Net Profit Margin	-1.5K%	↑ 685.52%

	Q4 FY24	Q/Q Change
Revenue	$1.6M	↑ 0.0%
Net Income	$-24.0M	↑ 0.0%
Net Profit Margin	-1.5K%	↑ 0.0%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-58.5M	↓ 593.97%

	FY20	Y/Y Change
Profit	$-49.3M	↓ 15.59%

	FY21	Y/Y Change
Profit	$-78.3M	↑ 58.64%

	FY22	Y/Y Change
Profit	$-53.4M	↓ 31.83%

	FY23	Y/Y Change
Profit	$-47.4M	↓ 11.13%

	FY24	Y/Y Change
Profit	$-35.2M	↓ 25.84%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Profit	$-8.0M	↓ 39.74%

	Q4 FY23	Q/Q Change
Profit	$-8.0M	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$-9.6M	↑ 19.73%

	Q2 FY24	Q/Q Change
Profit	$-9.6M	↑ 0.0%

	Q3 FY24	Q/Q Change
Profit	$-1.7M	↓ 82.24%

	Q4 FY24	Q/Q Change
Profit	$-1.7M	↑ 0.0%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-57.8M	↓ 22.96%
Investing Cash Flow	$-1000.0K	↓ 13.27%
Financing Cash Flow	$71.6M	↑ 4.37%

	FY20	Y/Y Change
Operating Cash Flow	$-56.4M	↓ 2.47%
Investing Cash Flow	$-3.3M	↑ 227.3%
Financing Cash Flow	$137.0M	↑ 91.38%

	FY21	Y/Y Change
Operating Cash Flow	$-106.7M	↑ 89.27%
Investing Cash Flow	$-1.6M	↓ 49.68%
Financing Cash Flow	$114.5M	↓ 16.48%

	FY22	Y/Y Change
Operating Cash Flow	$-65.8M	↓ 38.34%
Investing Cash Flow	$-232.0K	↓ 85.91%
Financing Cash Flow	$-9.9M	↓ 108.62%

	FY23	Y/Y Change
Operating Cash Flow	$-63.3M	↓ 3.82%
Investing Cash Flow	$-194.0K	↓ 16.38%
Financing Cash Flow	$74.5M	↓ 854.83%

	FY24	Y/Y Change
Operating Cash Flow	$-48.5M	↓ 23.41%
Investing Cash Flow	$-97.0K	↓ 50.0%
Financing Cash Flow	$40.3M	↓ 45.97%

Q3 FY23

Q4 FY23

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-14.2M	↓ 12.5%
Investing Cash Flow	$-127.0K	↓ 893.75%
Financing Cash Flow	$-3.2M	↓ 108.3%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-13.3M	↓ 6.73%
Investing Cash Flow	$39.0K	↓ 130.71%
Financing Cash Flow	$34.8M	↓ 1181.98%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-10.3M	-
Investing Cash Flow	$23.0K	↓ 182.14%
Financing Cash Flow	$-1.9M	↓ 35.83%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-10.3M	↑ 0.0%
Investing Cash Flow	$313.5K	↑ 1263.04%
Financing Cash Flow	$-2.1M	↑ 10.12%

Mesoblast Technicals Summary

Sell

Neutral

Buy

Mesoblast is currently in a neutral trading position according to technical analysis indicators.

Mesoblast Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Mesoblast	-8.7%	-10.12%	99.28%	129.3%	-63.46%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Mesoblast	0.12	NA	0.0	-0.73	-0.21	-0.05	NA	0.4
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Mesoblast	Buy	$2.1B	-63.46%	0.12	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Organization	Mesoblast
Employees	73
CEO	Dr. Paul J. Simmons BSc, Ph.D.
Industry	Health Technology

Key Management of Mesoblast

Name	Title
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)	Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Eric A. Rose M.D.	Chief Medical Officer & Executive Director
Mr. Andrew Chaponnel B.Com.	Interim Chief Finance Officer
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)	General Counsel & Corporate Executive
Dr. Paul J. Simmons BSc, Ph.D.	Scientific Advisor to the Chief Executive Officer
Ms. Geraldine Storton B.Sc., M.B.A., MMS	Head of Regulatory Affairs & Quality Management
Mr. Justin Horst B.S.	Head of Manufacturing
Dr. Fiona See Ph.D.	Senior VP & Head of Translational Research
Mr. Marcelo Santoro	Chief Commercial Officer
Ms. Niva Sivakumar B.Com., L.L.B.	Joint Company Secretary

Important FAQs about investing in MESO Stock from India :

What is Mesoblast share price today?

Mesoblast share price today is $13.81 as on August 30, 2025 at 1:29 am IST at the close of the market. Mesoblast share today touched a day high of $14.08 and a low of $13.55.

What is the 52 week high and 52 week low for Mesoblast share?

Mesoblast share touched a 52 week high of $22.00 and a 52 week low of $6.00. Mesoblast stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $13.81, lower by 37.23% versus the 52 week high.

How to invest in Mesoblast Stock (MESO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Mesoblast on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mesoblast Shares that will get you 0.1086 shares as per Mesoblast share price of $13.81 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Mesoblast Stock (MESO) from India?

Indian investors can start investing in Mesoblast (MESO) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Mesoblast stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Mesoblast share’s latest price of $13.81 as on August 30, 2025 at 1:29 am IST, you will get 0.7241 shares of Mesoblast. Learn more about fractional shares .

What are the returns that Mesoblast has given to Indian investors in the last 5 years?

Mesoblast stock has given -63.46% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?